Antimicrobial resistance, a global health concern, is primarily driven by the misuse and overuse of antibiotics. This necessitates a judicious approach towards antibiotic use in clinical practice to optimize patient care. The objective of this article is to provide a comprehensive guide to the rational use of antibiotics.
Choosing the right antibiotic is crucial. It should be based on the suspected pathogen, patient's allergy history, and local antimicrobial resistance patterns. Empiric therapy should be narrowed down once culture and susceptibility results are available.
Administering the right dose and duration of antibiotics is vital to avoid under-treatment and resistance. Shorter durations are being advocated for many infections to minimize the risk of adverse effects and resistance.
A regular review of the antibiotic regimen is essential for de-escalation or discontinuation of therapy based on the patient's clinical response and microbiological data.
ASP are coordinated efforts within a healthcare institution to promote the appropriate use of antibiotics. They aim to improve patient outcomes, reduce microbial resistance, and decrease the spread of infections caused by multi-drug-resistant organisms.
Continuous education and training of healthcare professionals on antibiotic use and resistance are crucial. This includes understanding the principles of antimicrobial therapy, resistance mechanisms, and the impact of antibiotic misuse.
Optimizing antibiotic use is a shared responsibility that requires a collaborative approach. By adhering to these principles of rational antibiotic use, we can improve patient outcomes and combat the global threat of antibiotic resistance. Continued education, stewardship, and research are critical to achieving these goals.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation